{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:53:25Z","timestamp":1791500005861,"version":"4.3.4"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adalimumab is the only FDA\u2010approved biologic for hidradenitis suppurativa (HS). In the setting of increasing obesity rates worldwide, the relationship between adalimumab efficacy for HS and BMI is essential to understand. We assessed this relationship through markers of disease severity and inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Institutional review board\u2010approved retrospective chart review of Montefiore\/Einstein HS Center (HSC) patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200957) treated with adalimumab. The relationship between BMI and adalimumab efficacy was assessed through disease severity (HS\u2010Physician Global Assessment [HS\u2010PGA] 0 and Numerical Rating Scale Pain [NRS\u2010Pain]) and inflammatory markers (erythrocyte sedimentation rate [ESR], C\u2010reactive protein [CRP], and interleukin\u20106 [IL\u20106]). A BMI\u2009\u2265\u200930 is defined as obese; BMI\u2009&lt;\u200930 is defined as non\u2010obese.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age was 35.8\u2009\u00b1\u200913.0\u2009years. After adalimumab therapy, those with BMI\u2009&lt;\u200930 experienced significant reductions in HS\u2010PGA (\u22121.5\u2009\u00b1\u20090.9;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u20090.0001) and NRS\u2010Pain (\u22121.6\u2009\u00b1\u20092.1;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u20090.0001), as well as mean decreases in inflammatory markers ESR, CRP, and IL\u20106 (\u221217.90\u2009\u00b1\u200923.6, \u22120.71\u2009\u00b1\u20091.4, \u22125.88\u2009\u00b1\u20097.9, respectively;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&gt;\u20090.05). Obese patients (BMI \u2265 30) experienced mean increases in HS\u2010PGA (+0.22\u2009\u00b1\u20090.8;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&gt;\u20090.05) and NRS\u2010Pain scores (+1.41\u2009\u00b1\u20093.5;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&gt;\u20090.05) as well as mean increases in ESR, CRP, and IL\u20106 (+2.62\u2009\u00b1\u200928.3, +0.44\u2009\u00b1\u20093.0, +2.35\u2009\u00b1\u20096.9, respectively;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&gt;\u20090.05). Comparing the cohorts, differences in changes in HS\u2010PGA, NRS\u2010Pain, ESR, and IL\u20106 after therapy are significantly different (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We identified significantly lower efficacy of adalimumab in HS patients with BMI\u2009\u2265\u200930 compared to those with BMI\u2009&lt;\u200930. Those with BMI\u2009\u2265\u200930 demonstrated signs of both clinical and physiological deterioration while on adalimumab. Future studies are needed to examine adalimumab dosing for HS patients with high BMI, as well as a critical reconsideration of weight\u2010based therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ijd.16565","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:05:07Z","timestamp":1672358707000},"page":"764-769","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Adalimumab efficacy is inversely correlated with body mass index (\n                    <scp>BMI<\/scp>\n                    ) in hidradenitis suppurativa"],"prefix":"10.1111","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4200-6801","authenticated-orcid":false,"given":"Avigdor","family":"Nosrati","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Dermatology Albert Einstein College of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7956-9045","authenticated-orcid":false,"given":"McCall E.","family":"Torpey","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Dermatology Albert Einstein College of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Shokrian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Dermatology Albert Einstein College of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-0279","authenticated-orcid":false,"given":"Peter Y.","family":"Ch'en","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Dermatology Albert Einstein College of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2104-7337","authenticated-orcid":false,"given":"Tyler M.","family":"Andriano","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Dermatology Albert Einstein College of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6900-3400","authenticated-orcid":false,"given":"Gabrielle","family":"Benesh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Dermatology Albert Einstein College of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley D.","family":"Heibel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Dermatology Albert Einstein College of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4151-1133","authenticated-orcid":false,"given":"H. Dean","family":"Hosgood","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Dermatology Albert Einstein College of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina L.","family":"Campton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Dermatology Albert Einstein College of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7774-1825","authenticated-orcid":false,"given":"Steven R.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Dermatology Albert Einstein College of Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.07.003"},{"issue":"8","key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/ddg.12067","article-title":"Depression is a frequent co\u2010morbidity in patients with acne inversa","volume":"11","author":"Kurek A","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.068"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12966"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.186"},{"issue":"8","key":"e_1_2_7_7_1","first-page":"1547","article-title":"Hidradenitis suppurativa: a treatment challenge","volume":"72","author":"Shah N","year":"2005","journal-title":"Am Fam Physician"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.09.071"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S199862"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200418020-00005"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19863"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-12-201212180-00004"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17919"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2014.2278"},{"issue":"1","key":"e_1_2_7_15_1","first-page":"145","article-title":"Obesity decreases clinical efficacy and levels of adalimumab in patients with\u00a0ankylosing spondylitis","volume":"35","author":"Rosas J","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_16_1","volume-title":"Prevalence of obesity among adults and youth: United States, 2015\u20132016. NCHS data brief, no 288","author":"Hales CM","year":"2017"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195123"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.603281"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000501771"},{"issue":"1","key":"e_1_2_7_20_1","article-title":"Pain in hidradenitis suppurativa: a cross\u2010sectional study of 1,795 patients","volume":"101","author":"Krajewski PK","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16244"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503606"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.16565","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.16565","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.16565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T23:01:28Z","timestamp":1697065288000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.16565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/ijd.16565"],"URL":"https:\/\/doi.org\/10.1111\/ijd.16565","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"2022-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}